This page uses content from Wikipedia and is licensed under CC BY-SA.

Patritumab

Patritumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1]

Clinical trials

It is in a phase 2 clinical trial for squamous cell cancer of the head and neck.[2]

It is to be included in a new arm of the I-SPY 2 breast cancer trial.[3]

References

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
  2. ^ A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck
  3. ^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. Oct 2016